TCR2 Therapeutics (TCRR) PT Lowered to $23 at Piper Sandler
- Wall Street ends first day of third quarter with solid rebound
- Tesla (TSLA) Delivered 254,695 EV Units in Q2, Below Consensus
- Goldman Sachs Warns Clients of More Equity Market Losses in Second Half of 2022
- Kohl's (KSS) Falls 15% After Ending Sale Talks With Franchise Group and Issuing Q2 Warning
- General Motors Warns It Has 95k Vehicles in Inventory Without Certain Components
Piper Sandler analyst Do Kim lowered the price target on TCR2 Therapeutics (NASDAQ: TCRR) to $23.00 (from $26.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Perpetual Ltd (PPT:AU) (PRPLF) PT Lowered to AUD34 at Credit Suisse
- Credit Suisse Upgrades Platinum Asset Management Ltd. (PTM:AU) (PTMGF) to Neutral
- Pendal Group Ltd (PDL:AU) PT Lowered to AUD4 at Credit Suisse
Create E-mail Alert Related CategoriesAnalyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!